Travere Therapeutics, Inc. is a biopharmaceutical company. Co. is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). Co.'s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. We show 19 historical shares outstanding datapoints in our TVTX shares outstanding history coverage, used to compute TVTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TVTX market cap history over the course of time is important for investors
interested in comparing TVTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TVTX versus a peer is one thing; comparing
TVTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TVTX can fluctuate over the course of history.
With this page we aim to empower investors researching TVTX by allowing them to research the TVTX market cap history. |
Free TVTX Email Alerts:
Video: The Importance of Market Cap
